@article{KleinBarthelsJoheetal.2020,
  author    = {Klein, Philipp and Barthels, Fabian and Johe, Patrick and Wagner, Annika and Tenzer, Stefan and Distler, Ute and Le, Thien Anh and Schmid, Paul and Engel, Volker and Engels, Bernd and Hellmich, Ute A. and Opatz, Till and Schirmeister, Tanja},
  title     = {Naphthoquinones as covalent reversible inhibitors of cysteine proteases — studies on inhibition mechanism and kinetics},
  series = {Molecules},
  volume    = {25},
  journal   = {Molecules},
  number    = {9},
  issn      = {1420-3049},
  doi       = {10.3390/molecules25092064},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-203791},
  year      = {2020},
  abstract  = {The facile synthesis and detailed investigation of a class of highly potent protease inhibitors based on 1,4-naphthoquinones with a dipeptidic recognition motif (HN-l-Phe-l-Leu-OR) in the 2-position and an electron-withdrawing group (EWG) in the 3-position is presented. One of the compound representatives, namely the acid with EWG = CN and with R = H proved to be a highly potent rhodesain inhibitor with nanomolar affinity. The respective benzyl ester (R = Bn) was found to be hydrolyzed by the target enzyme itself yielding the free acid. Detailed kinetic and mass spectrometry studies revealed a reversible covalent binding mode. Theoretical calculations with different density functionals (DFT) as well as wavefunction-based approaches were performed to elucidate the mode of action.},
  language  = {en}
}
@techreport{AngnideBielitskaBorchertetal.2020,
  author    = {Angnide, Enarile and Bielitska, Iryna and Borchert, Leon and Braun, Louisa and B{\"u}hler, Pascal and Chen, Xinyue and Ho, Katherina and Hofmann, Lena and Kebekus, Melvin and Kubsch, Torbj{\"o}rn and Li, Alexander and Lin, Simon and Mischer, Andreas and Mogus, Mateja and Schmid, Fabian and Schneidawind, Luisa and Voss, Manuela and Wilson, Claire and Wieteska, Filip and Yu, Linda},
  title     = {Chinese Entanglements in Lower Franconian Business},
  editor    = {Lindner, Jonas and Fischer, Doris},
  doi       = {10.25972/OPUS-20987},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-209876},
  pages     = {219},
  year      = {2020},
  abstract  = {Using own survey data and interviews, this study analyzes how businesses in Lower Franconia (Unterfranken) are entangled with China. Starting with a bird's-eye-view of the current situation, the study goes on to provide valuable insights from five specific industries. The study shows that a majority of the analyzed firms have some sort of ties to China, be it through Chinese customers, import/export activities, or else.},
  subject      = {China},
  language  = {en}
}
@article{HanitschBaumannBoztugetal.2020,
  author    = {Hanitsch, Leif and Baumann, Ulrich and Boztug, Kaan and Burkhard-Meier, Ulrike and Fasshauer, Maria and Habermehl, Pirmin and Hauck, Fabian and Klock, Gerd and Liese, Johannes and Meyer, Oliver and M{\"u}ller, Rainer and Pachlopnik-Schmid, Jana and Pfeiffer-Kascha, Dorothea and Warnatz, Klaus and Wehr, Claudia and Wittke, Kirsten and Niehues, Tim and von Bernuth, Horst},
  title     = {Treatment and management of primary antibody deficiency: German interdisciplinary evidence-based consensus guideline},
  series = {European Journal of Immunology},
  volume    = {50},
  journal   = {European Journal of Immunology},
  number    = {10},
  doi       = {10.1002/eji.202048713},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-225731},
  pages     = {1432 -- 1446},
  year      = {2020},
  abstract  = {This evidence-based clinical guideline provides consensus-recommendations for the treatment and care of patients with primary antibody deficiencies (PADs). The guideline group comprised 20 clinical and scientific expert associations of the German, Swiss, and Austrian healthcare system and representatives of patients. Recommendations were based on results of a systematic literature search, data extraction, and evaluation of methodology and study quality in combination with the clinical expertise of the respective representatives. Consensus-based recommendations were determined via nominal group technique. PADs are the largest clinically relevant group of primary immunodeficiencies. Most patients with PADs present with increased susceptibility to infections, however immune dysregulation, autoimmunity, and cancer affect a significant number of patients and may precede infections. This guideline therefore covers interdisciplinary clinical and therapeutic aspects of infectious (e.g., antibiotic prophylaxis, management of bronchiectasis) and non-infectious manifestations (e.g., management of granulomatous disease, immune cytopenia). PADs are grouped into disease entities with definitive, probable, possible, or unlikely benefit of IgG-replacement therapy. Summary and consensus-recommendations are provided for treatment indication, dosing, routes of administration, and adverse events of IgG-replacement therapy. Special aspects of concomitant impaired T-cell function are highlighted as well as clinical data on selected monogenetic inborn errors of immunity formerly classified into PADs (APDS, CTLA-4-, and LRBA-deficiency).},
  language  = {en}
}